Search

Sort Results

Search results

Current filters: HIV, Treatment, Research summary, English, HIV drugs, Raltegravir (Isentress, Isentress HD)

10 search results

CDC recommends use of raltegravir (Isentress) for PEP

From TreatmentUpdate 228
2018, CATIE
Research summary - Webpage

Isentress HD in clinical trials

From TreatmentUpdate 221
2017, CATIE
Research summary - Webpage

Isentress HD—a new once-daily formulation of raltegravir approved in Canada

From TreatmentUpdate 221
2017, CATIE
Research summary - Webpage

Canadian researchers review the use of raltegravir in pregnancy

2016, CATIE
Research summary - Webpage

U.S. study reviews use and impact of integrase inhibitors in pregnancy

2016, CATIE
Research summary - Webpage

Comparing the tolerability and effectiveness of initial therapy

From TreatmentUpdate 202
2014, CATIE
Research summary - Webpage

Dual therapy with raltegravir and darunavir

From TreatmentUpdate 202
2014, CATIE
Research summary - Webpage

Raltegravir in women and reduced soluble CD14

From TreatmentUpdate 201
2014, CATIE
Research summary - Webpage

Dolutegravir vs. raltegravir—results after two years

From TreatmentUpdate 199
2013, CATIE
Research summary - Webpage

Australia: raltegravir and muscle weakness—a rare complication

From TreatmentUpdate 193
2012, CATIE
Research summary - Webpage